中国预防性人乳头瘤病毒疫苗研制及应用

陈祺; 吴婷; 张军; 夏宁邵

doi:10.16462/j.cnki.zhjbkz.2023.03.001

中国预防性人乳头瘤病毒疫苗研制及应用

doi: 10.16462/j.cnki.zhjbkz.2023.03.001

361102 厦门，厦门大学公共卫生学院，国家传染病诊断试剂与疫苗工程技术研究中心，分子疫苗学和分子诊断学国家重点实验室

基金项目:

国家自然科学基金 82273640

中央高校基本科研业务费专项资金资助 20720220006

详细信息

通讯作者:
夏宁邵，E-mail: nsxia@xmu.edu.cn

中图分类号: R186.3
计量
- 文章访问数: 494
- HTML全文浏览量: 417
- PDF下载量: 135
- 被引次数: 0
出版历程
- 收稿日期: 2023-02-15
- 修回日期: 2023-02-22
- 网络出版日期: 2023-04-04
- 刊出日期: 2023-03-10

Development and application of prophylactic human papilloma virus vaccines in China

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China

Funds:

National Natural Science Foundation of China 82273640

Fundamental Research Funds for the Central Universities 20720220006

More Information

Corresponding author: XIA Ning-shao, E-mail: nsxia@xmu.edu.cn

摘要

摘要: 人乳头瘤病毒(human papilloma virus, HPV)疫苗是预防HPV感染及相关疾病的有效手段。近年来中国HPV疫苗研发领域蓬勃发展，已有两个国产一代疫苗上市，第二代疫苗临床评价正顺利开展，第三代疫苗如“二十价”疫苗研发已取得实质进展，实现从“跟跑”到“领跑”的角色转变。当前中国全面快速推进宫颈癌消除工作的时机日趋成熟。在此关键时刻，应注重提升HPV疫苗临床评价能力、加强HPV疫苗上市后安全性主动监测体系建设、整合多平台信息以搭建HPV疫苗真实世界保护效果评价体系、积极拓宽适用人群和产品适应证、加快国产疫苗国际化进程，为全球宫颈癌防控贡献中国智慧和力量。
- 国产人乳头瘤病毒疫苗 /
- 宫颈癌 /
- 消除
Abstract: Human papilloma virus vaccine is an effective tool to prevent HPV infection and related diseases. In recent years, the development of HPV vaccines had made great progress. Two domestic first-generation HPV vaccines have been licensed, several second-generation HPV vaccines are under clinical evaluations, and the development of the third-generation vaccines, such as "20 valent" vaccines, has made substantial progress. There advances in vaccines indicates that China has changed from "follower" to "leader" in the field of HPV vaccine research. The time for launching the campaign of rapid elimination of cervical cancer in China is ripe. At this time point, it is necessary to improve the clinical evaluation capabilities for HPV vaccines, construct the system of active post-marketing safety monitoring, integrate information across multiple platforms to establish an evaluation system for the real-world effectiveness of HPV vaccines, expand the target population and indications of the product, and accelerate the internationalization of domestic HPV vaccines, and contribute China's wisdom to global cervical cancer prevention and control.
- Domestic human papilloma virus vaccine /
- Cervical cancer /
- Elimination

HTML全文

参考文献(13)

[1]	de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
[2]	World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022[EB/OL]. (2022-12-16)[2023-02-14]. https://www.who.int/publications/i/item/who-wer9750-645-672.
[3]	妇幼健康司. 关于印发加速消除宫颈癌行动计划(2023―2030年)的通知[EB/OL]. (2023-01-20)[2023-02-14]. http://www.nhc.gov.cn/fys/s3582/202301/04b918b28fb0418b9ca00dabcd29e1dc.shtml. Department of Maternal and Child Health. Notice on issuing the action plan for accelerating the elimination of cervical cancer (2023-2030)[EB/OL]. (2023-01-20)[2023-02-14]. http://www.nhc.gov.cn/fys/s3582/202301/04b918b28fb0418b9ca00dabcd29e1dc.shtml.
[4]	Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019[J]. Prev Med, 2021, 144: 106399. DOI: 10.1016/j.ypmed.2020.106399.
[5]	广东省预防医学会宫颈癌防治专业委员会. 消除子宫颈癌之HPV疫苗应用广东专家共识[J]. 中国医师杂志, 2021, 23(9): 1303-1315. DOI: 10.3760/cma.j.cn431274-20210819-00911. Cervical Cancer Prevention Committee of Guangdong. Preventive medicine association, Guangdong expert consensus on HPV vaccine application to eliminate cervical cancer[J]. J Chin Phys, 2021, 23(9): 1303-1315. DOI: 10.3760/cma.j.cn431274-20210819-00911.
[6]	Li Z, Song S, He M, et al. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity[J]. Nat Commun, 2018, 9(1): 5360. DOI: 10.1038/s41467-018-07199-6.
[7]	Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial[J]. Cancer Med, 2017, 6(1): 12-25. DOI: 10.1002/cam4.86.
[8]	Wei L, Xie X, Liu J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37(27): 3617-3624. DOI: 10.1016/j.vaccine.2018.08.009.
[9]	Zhao FH, Wu T, Hu YM, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced human papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial[J]. Lancet Infect Dis, 2022, 22(12): 1756-1768. DOI: 10.1016/S1473-3099(22)00435-2.
[10]	中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8): 761-803. DOI: 10.3760/cma.j.issn.0253-9624.2019.08.001. Vaccine and Immunization Branch, Chinese Preventive Medicine Association. Expert consensus on immunological prevention of human papillomavirus-related diseases[J]. Chin J Prev Med, 2019, 53(8): 761-803. DOI: 10.3760/cma.j.issn.0253-9624.2019.08.001.
[11]	World Health Organization. Global Advisory Committee on Vaccine Safety, report of meeting held 7-8 June[EB/OL]. (2017-07-14)[2023-02-14]. https://www.who.int/publications/i/item/WER9228.
[12]	江伟, 刘艳, 杜渐, 等. 2017―2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73, 77. DOI: 10.19485/j.cnki.issn2096-5087.2023.01.017. Jiang W, Liu Y, Du J, et al. Surveillance of adverse events following immunization with human papillomavirus vaccines in Hangzhou City from 2017 to 2021[J]. Prev Med, 2023, 35(1): 71-73, 77. DOI: 10.19485/j.cnki.issn2096-5087.2023.01.017.
[13]	Xia C, Xu X, Zhao X, et al. Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study[J]. BMC Med, 2021, 19(1): 62. DOI: 10.1186/s12916-021-01930-9.